Royalty Pharma Plc
$ 58.42
1.96%
21 Jul - close price
- Market Cap 32,992,305,000 USD
- Current Price $ 58.42
- High / Low $ 58.44 / 56.90
- Stock P/E 30.64
- Book Value 15.53
- EPS 1.87
- Next Earning Report 2026-08-05
- Dividend Per Share $0.90
- Dividend Yield 1.54 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.14 %
- 52 Week High 59.44
- 52 Week Low 33.57
About
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$59.89
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-11 | 2025-11-05 | 2025-08-06 | 2025-05-08 | 2025-02-11 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-08 | 2023-08-08 |
| Reported EPS | 1.3 | 1.47 | 1.17 | 1.14 | 1.06 | 1.15 | 1.04 | 0.96 | 0.98 | 1.52 | 0.79 | 0.84 |
| Estimated EPS | 1.18 | 1.33 | 1.11 | 1.03 | 0.95 | 1.05 | 0.93 | 0.97 | 0.98 | 1 | 0.77 | 0.81 |
| Surprise | 0.12 | 0.14 | 0.06 | 0.11 | 0.11 | 0.1 | 0.11 | -0.01 | 0 | 0.52 | 0.02 | 0.03 |
| Surprise Percentage | 10.1695% | 10.5263% | 5.4054% | 10.6796% | 11.5789% | 9.5238% | 11.828% | -1.0309% | 0% | 52% | 2.5974% | 3.7037% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.27 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-10 | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-13 | 2024-06-14 | 2024-03-15 |
| Amount | $0.235 | $0.235 | $0.22 | $0.22 | $0.22 | $0.22 | $0.21 | $0.21 | $0.21 | $0.21 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RPRX
2026-07-17 20:21:00
Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation in the sector, holding royalties on over 35 commercial products and 19 development-stage candidates. This dividend announcement reflects strong financial health and a commitment to shareholder value, though it also raises questions about reinvestment opportunities and future strategic plans.
2026-07-17 20:10:10
Royalty Pharma (Nasdaq: RPRX) has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share. This dividend will be paid on September 10, 2026, to shareholders who are on record as of August 14, 2026. Royalty Pharma is known as the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry.
2026-07-04 09:41:24
This article lists various ETFs that include Royalty Pharma Plc Class A (RPD) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of RPD, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. The ETFs cover a range of investment focuses, from diversified total market funds to sector-specific and ESG-focused options.
2026-07-02 20:10:03
Royalty Pharma plc's EVP Christopher Hite sold 130,000 Class A Ordinary Shares on June 30, 2026, as part of a pre-arranged 10b5-1 trading plan. The shares were sold at weighted average prices between approximately $56 and $57. Hite now directly holds 40,000 shares, with an additional 461,953 shares held indirectly through SCH Investment Partners LLC.
2026-07-02 20:10:03
Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares on July 1, 2026, at a weighted average price of $55.8802 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following the sale, Urist directly holds no Class A shares but maintains an indirect holding of 19,020 shares through an IRA.
2026-07-01 20:40:38
Royalty Pharma plc insider Marshall Urist filed Form 144 notices for proposed sales of Common Stock, totaling approximately $1.95 million across three transactions in May and June 2026. The filing also disclosed an Equity Performance Award of 9,099 Class A Ordinary Shares granted on May 8, 2026, as part of the company's equity compensation program. While the sales don't explicitly link to the award, the various transactions relate to Urist's holdings.
